scholarly journals New repurposed rolapitant in nanovesicular systems for lung cancer treatment: Development, in-vitro assessment and in-vivo biodistribution study

2022 ◽  
pp. 106119
Author(s):  
Mohamed Fawzi Kabil ◽  
Maha Nasr ◽  
Ismail T. Ibrahim ◽  
Yasser A. Hassan ◽  
Ibrahim M. El-Sherbiny
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Biodistribution Study ◽  
Treatment Development ◽  
Lung Cancer Treatment ◽  
In Vivo Biodistribution ◽  
In Vitro Assessment ◽  
Development In Vitro

scholarly journals In Vitro and in Vivo Antitumor Evaluation of Berbamine for Lung Cancer Treatment

2014 ◽  
Vol 15 (4) ◽  
pp. 1767-1769 ◽  
Author(s):  
Zhi-Bo Hou ◽  
Kai-Jin Lu ◽  
Xiao-Li Wu ◽  
Cong Chen ◽  
Xin-En Huang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Lung Cancer Treatment ◽  
Antitumor Evaluation

scholarly journals Aerosolized Niosome Formulation Containing Gemcitabine and Cisplatin for Lung Cancer Treatment: Optimization, Characterization and In Vitro Evaluation

Pharmaceutics ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 59
Author(s):  
Norfatin Izzatie Mohamad Saimi ◽  
Norazlinaliza Salim ◽  
Noraini Ahmad ◽  
Emilia Abdulmalek ◽  
Mohd Basyaruddin Abdul Rahman
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Normal Lung ◽  
Alternative Formulation ◽  
Treatment Optimization ◽  
Lung Cancer Treatment ◽  
Diffusion Technique ◽  
Dialysis Bag ◽  
Cytotoxicity Effects

Gemcitabine (Gem) and cisplatin (Cis) are currently being used for lung cancer treatment, but they are highly toxic in high dosages. This research aimed to develop a niosome formulation containing a low-dosage Gem and Cis (NGC), as an alternative formulation for lung cancer treatment. NGC was prepared using a very simple heating method and was further optimized by D-optimal mixture design. The optimum NGC formulation with particle size, polydispersity index (PDI), and zeta potential of 166.45 nm, 0.16, and −15.28 mV, respectively, was obtained and remained stable at 27 °C with no phase separation for up to 90 days. The aerosol output was 96.22%, which indicates its suitability as aerosolized formulation. An in vitro drug release study using the dialysis bag diffusion technique showed controlled release for both drugs up to 24 h penetration. A cytotoxicity study against normal lung (MRC5) and lung cancer (A549) cell lines was investigated. The results showed that the optimized NGC had reduced cytotoxicity effects against both MRC5 and A549 when compared with the control (Gem + Cis alone) from very toxic (IC50 < 1.56 µg/mL) to weakly toxic (IC50 280.00 µg/mL) and moderately toxic (IC50 = 46.00 µg/mL), respectively, after 72 h of treatment. These findings revealed that the optimized NGC has excellent potential and is a promising prospect in aerosolized delivery systems to treat lung cancer that warrants further investigation.

Therapeutic delivery of microRNA-143 by cationic lipoplexes for non-small cell lung cancer treatment in vivo

2019 ◽  
Vol 145 (12) ◽  
pp. 2951-2967 ◽  
Author(s):  
Qianqian Jiang ◽  
Yue Yuan ◽  
Yi Gong ◽  
Xinmei Luo ◽  
Xiaolan Su ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Treatment ◽  
Therapeutic Delivery

scholarly journals Aptamers in Non-Small Cell Lung Cancer Treatment

Molecules ◽  
2020 ◽  
Vol 25 (14) ◽  
pp. 3138 ◽  
Author(s):  
Irena Wieleba ◽  
Kamila Wojas-Krawczyk ◽  
Paweł Krawczyk
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Small Cell Lung Cancer ◽  
Cancer Progression ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Production Costs ◽  
Small Cell Lung ◽  
Lung Cancer Treatment

Aptamers are short, single-stranded oligonucleotides which are capable of specifically binding to single molecules and cellular structures. Aptamers are also known as “chemical antibodies”. Compared to monoclonal antibodies, they are characterized by higher reaction specificity, lower molecular weight, lower production costs, and lower variability in the production stage. Aptamer research has been extended during the past twenty years, but only Macugen® has been accepted by the Food and Drug Administration (FDA) to date, and few aptamers have been examined in clinical trials. In vitro studies with aptamers have shown that they may take part in the regulation of cancer progression, angiogenesis, and metastasis processes. In this article, we focus on the potential use of aptamers in non-small cell lung cancer treatment.

Cross-linked hyaluronic acid sub-micron particles: in vitro and in vivo biodistribution study in cancer xenograft model

2013 ◽  
Vol 24 (6) ◽  
pp. 1473-1481 ◽  
Author(s):  
F. Rosso ◽  
V. Quagliariello ◽  
C. Tortora ◽  
A. Di Lazzaro ◽  
A. Barbarisi ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Xenograft Model ◽  
Biodistribution Study ◽  
In Vivo Biodistribution

scholarly journals Novel Frog Skin-Derived Peptide Dermaseptin-PP for Lung Cancer Treatment: In vitro/vivo Evaluation and Anti-tumor Mechanisms Study

2020 ◽  
Vol 8 ◽  
Author(s):  
Ziyi Dong ◽  
Haiyan Hu ◽  
Xianglong Yu ◽  
Li Tan ◽  
Chengbang Ma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Frog Skin ◽  
Lung Cancer Treatment

Engineering of glycyrrhizin capped gold nanoparticles for liver targeting: in vitro evaluation and in vivo biodistribution study

RSC Advances ◽  
2016 ◽  
Vol 6 (51) ◽  
pp. 44944-44954 ◽  
Author(s):  
Shaivee Borker ◽  
Milind Patole ◽  
Alpana Moghe ◽  
Varsha Pokharkar
Keyword(s):  
Gold Nanoparticles ◽  
Antiviral Drug ◽  
Biodistribution Study ◽  
Liver Targeting ◽  
In Vitro Evaluation ◽  
In Vivo Biodistribution

Glycyrrhizin reduced and stabilized gold nanoparticles as carriers of antiviral drug lamivudine. The presence of glycyrrhizin enhanced uptake and localization of drug loaded gold nanoparticles in hepatocytes.

The Rationale for Repurposing Sildenafil for Lung Cancer Treatment

2018 ◽  
Vol 18 (3) ◽  
pp. 367-374 ◽  
Author(s):  
Theodore Keats ◽  
Rhonda J. Rosengren ◽  
John C. Ashton
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Cancer Cells ◽  
Clinical Investigation ◽  
Tumour Size ◽  
Chemotherapeutic Agents ◽  
Metabolic Effects ◽  
Clinical Effects ◽  
Lung Cancer Treatment

There is now a considerable body of evidence for sildenafil possessing anticancer properties. In this article, we argue the case for testing sildenafil as a lung cancer therapy chemoadjuvant. Currently, lung cancer is a disease with insufficient treatment options, with only 20% of patients responding to systemic chemotherapy, and even incremental potential improvements should be explored. We review the literature concerning the biochemical, physiological and metabolic effects on cancer cells by sildenafil alone, and when combined with chemotherapeutic agents. Most studies have shown that sildenafil is cytotoxic to cancer cells, both as a monotherapy and as a chemoadjuvant. Sildenafil enhances cancer cell apoptosis when used as a chemoadjuvant both in vitro and in vivo. In particular, in rodent experiments sildenafil has decreased tumour size compared to chemotherapy alone. Sildenafil has also been proven as an agent to decrease drug-efflux by cancer cells and increases blood perfusion to lung tissue, which can potentially increase the dosage of chemotherapeutic agents delivered to lung cancer cells compared to healthy tissue. In addition, the proven clinical effects of sildenafil on other lung diseases suggest that it could improve other patient outcomes, such as right ventricular function and quality of life. Sildenafil may also extend the half-life of docetaxel and some small molecule inhibitors used in lung cancer treatment by acting as an inhibitor of CYP3A4. We conclude that the evidence strongly warrants clinical investigation into the use of sildenafil as an agent for the treatment of lung-cancer.

Sign in / Sign up

Export Citation Format

Share Document